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 Abstract 
  Background/Aims:   A l t h o u g h  r e c e n t  e v i d e n c e  h a s  i n d i c a t e d  t h a t  ty p e  2  d i a b e t e s  m e l l i t u s  
(T2DM) in the elderly is a risk factor for cognitive dysfunction or dementia, few studies have 
prospectively observed this potential cognitive decline. In the current study, we performed 
cognitive assessments at baseline and after 3 years in the same patient group in an attempt to 
reveal the contributions of diabetes-related factors to the increased decline in cognitive func-
tion in elderly patients with T2DM.   Methods:   We recruited 55 consecutive T2DM patients with 
a Mini-Mental State Examination (MMSE) score   6  24 from the Diabetic Center at the Chubu Ro-
sai Hospital. These patients ranged in age from 65 to 85 years. Cognitive and clinical assess-
ments, including brain MRI, were performed at baseline and at the 3-year follow-up.   Results:  
The higher plasma insulin and HbA  1c   levels observed at baseline were significantly associated 
with a worse cognitive performance at baseline and a more neurocognitive decline at the fol-
low-up visit.  Conclusion:  The current prospective study suggests that higher insulin and glyco-
hemoglobin levels may be associated with diabetes-related cognitive dysfunction. 
  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  Recent evidence has indicated that type 2 diabetes mellitus (T2DM) in the elderly is a 
risk factor for cognitive dysfunction or dementia   [1]  . Although several mechanisms have 
been proposed, the precise mechanisms that underlie T2DM-related cognitive dysfunction 
or the development of dementia have not yet been elucidated   [2]  .
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    High glucose concentrations, a major pathological characteristic of diabetes, may have 
toxic effects on neurons in the brain through osmotic insults and oxidative stress  [3] . Chron-
ically high glucose also leads to enhanced formation of advanced glycation end products, 
which have potentially toxic effects on neurons   [4]  .
  T2DM, especially in conjunction with obesity, is characterized by insulin resistance and/
or hyperinsulinemia. Insulin resistance is defined as an inadequate response of target tissues 
(e.g. skeletal muscle, liver, and adipose tissue) to circulating insulin, and this condition is of-
ten accompanied by elevated insulin levels. Insulin is transported across the blood-brain 
barrier via an active transport mechanism into the central nervous system (CNS)   [5]   and is 
assumed to exert several effects on synapses and neurons. Furthermore, insulin resistance 
may also occur in the CNS   [6]  . Several studies have reported that hyperinsulinemia or insu-
lin resistance is associated with cognitive dysfunction or dementia   [7–10]  .
    Small vessel disease in the brain (white matter lesions and lacunae) is frequently associ-
ated with T2DM. Although there is general consensus regarding the negative impact of large 
vascular lesions on cognition, the role that small vessel disease plays in cognitive dysfunction 
remains unclear. W e have previously reported that small vessel diseases affect cognitive 
function in older diabetics without overt dementia or symptomatic stroke   [11]  .
  Although several factors have been hypothesized to contribute to diabetes-related cogni-
tive dysfunction, available data are mainly from a cross-sectional analysis   [12]  . In several 
prospective studies, the presence of diabetes has been reported to affect cognitive function 
  [12]  , but few prospective studies have investigated the effect of specific diabetes-related fac-
tors   [13, 14]  . In two studies, results of the impact of glucose control levels measured by gly-
cohemoglobin on cognitive function were inconsistent, but there have been no reports on the 
effects of insulin levels on cognitive function in diabetics based on prospective studies. In 
this study, we performed cognitive assessments at baseline and 3 years later in the same pa-
tient group. We examined the contribution of vascular and diabetes-related factors at base-
line to the decline in cognitive function in elderly patients with T2DM.
  M e t h o d s  
 Patients 
  We consecutively recruited 58 patients with T2DM   [15]   from the Diabetic Center at the 
Chubu Rosai Hospital. These patients ranged in age from 65 to 85 years. The exclusion cri-
teria were as follows: a history of symptomatic stroke, malignancy, inflammatory disease, 
severe microvascular complications (such as renal failure), and severe cardiovascular disease 
(such as myocardial infarction and unstable angina). None of the patients exhibited audio-
visual deficiencies that would prevent them from participating in cognitive function tests. 
The Mini-Mental State Examination (MMSE) scores of these patients were 24 and above at 
baseline.
    An ethical committee approved the study, and all of the study patients provided their 
written informed consent prior to the investigation. After giving informed consent, patients 
were individually administered the cognitive function tests both at baseline (from April to 
June 2006) and at the 3-year follow-up (from April to May 2009). On the day of assessment, 
the patients had breakfast as usual, and the test was performed in the morning. Prior to the 
assessment, doctors performed a general physical checkup on the patients. Three of 58 pa-
tients did not participate in the follow-up assessment (2 female patients moved out of town 
and 1 male patient died from lung cancer). A total of 55 patients were analyzed in the current 
study.3
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  Cognitive  Tests 
  Cognitive function was assessed via the following structured performance tests, which 
were selected to cover a broad range of cognitive domains, including (i) mental status, (ii) 
verbal memory, (iii) complex psychomotor skills, and (iv) attention/executive function. 
Mental status was evaluated using the MMSE   [16]  , which is an assessment of general cogni-
tion. Verbal memory was tested with word recall using a word list, which is a subtest of the 
Alzheimer’s Disease Assessment Scale   [17]  . Immediately after the word list of 10 common 
nouns had been read, the respondents were asked to repeat as many words as they could 
recall in any order (immediate). After approximately 30 min of interference tasks, the re-
spondents were asked to recall the 10-word list again (delayed). In the current analysis, the 
number of words repeated in the delayed recall was used as an explanatory variable. Com-
plex psychomotor skills were examined using the Digit Symbol Substitution (DSS) test, 
which is a subtest of the Wechsler Adult Intelligence Scale-Revised  [18]  and has a score range 
of 0–93. Attention/executive function was assessed with the Stroop Color Word test (Stroop; 
Japanese version)  [19] . In this test, the amount of time (in seconds) required for the comple-
tion of a specific task is recorded. Specifically, the difference between the time required to 
read a word card versus the time required to read a dot card is calculated as an index of cog-
nitive response conflict. A larger time interval is interpreted as a more cognitive response 
conflict by interference in performance. Well-trained psychologist examiners administered 
all four tests in the same order to all the study patients. Depression was assessed by the Ge-
riatric Depression Scale-15 (GDS-15)   [20]  , which is a global test of depression with scores 
ranging from 0 to 15.
    Evaluation of the Patients 
 Hemoglobin A 1c  (HbA 1c ; reference range, 4.3–5.8%) was measured with a TOSHO auto-
mated glycohemoglobin analyzer (HLC-723G7; TOHSO Co., Tokyo, Japan). The value for 
HbA1c (%) is estimated as an NGSP equivalent value (%) calculated by the formula HbA1c
(%) = HbA1c (JDS) (%) + 0.4%, considering the relational expression of HbA1c (JDS) (%) mea-
sured by the previous Japanese standard substance and measurement methods and HbA1c 
(NGSP) [21]. Plasma insulin was assayed by radioimmunoassay. Plasma insulin was assayed 
by chemiluminescent enzyme immunoassay.
   Assessment of Brain Lesions.   Silent cerebral infarction (SCI) was diagnosed using mag-
netic resonance imaging (MRI; GE Signa Horizon, 1.5 T; GE, Milwaukee, Wisc., USA). They 
were defined as irregular areas of high signal intensity   1  3 mm in diameter on T  2 -weighted 
images, low-signal intensity areas on T  1  -weighted images, and areas of higher intensity than 
that of the cerebrospinal fluid in proton density images or fluid-attenuated inversion recov-
ery images. Lesions   !  3 mm in diameter or lesions with signal intensities similar to those of 
the cerebrospinal fluid in proton images and fluid-attenuated inversion recovery images 
were excluded because of the high possibility that they were enlarged perivascular spaces, 
even if they demonstrated high signals on T  2 -weighted images and low signals on T  1 -weight-
ed images.
    A modified rating scale was used to describe the different types of hyperintense signal 
abnormalities surrounding the ventricles and in the deep white matter  [22] . Briefly, periven-
tricular hyperintensity (PVH) was graded as 0 = absent, 1 = ‘caps’ or pencil-thin lining, 2 = 
smooth ‘halo’, and 3 = irregular PVH extending into the deep white matter. Separate deep 
white matter hyperintense lesions (WMLs) were rated as 0 = absent, 1 = punctate foci, 2 = 
beginning confluence of foci, and 3 = large confluent areas.4
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  D a t a   A n a l y s i s  
 All data are presented means  8  SD. Multiple regression analysis was performed in order 
to search for an association between the covariants at baseline and the performance on cog-
nitive function testing. The explanatory variables used in this study included age, gender 
(male = 1, female = 0), years of education, HbA  1c  , serum insulin (log), the number of SCIs, 
and WML and PVH grading (0–3).
    Multiple linear regression analyses were also performed to determine a longitudinal as-
sociation between the covariants at baseline and changes between baseline and 3-year cogni-
tive function tests. The objective variables included the score of each cognitive assessment or 
the change in scores from baseline to follow-up (subtracting the baseline score from the fol-
low-up score), which was adjusted for age, gender, education, body mass index, GDS-15, 
mean blood pressure [diastolic blood pressure + (systolic blood pressure – diastolic blood 
pressure)/3], and T2DM duration. To analyze changes in scores, baseline score-based adjust-
ments were also included.
  R e s u l t s  
  Table 1  summarizes the characteristics of the patients included in this study. The cogni-
tive assessments were performed at baseline and 3 years later.   Table 2   summarizes the scores 
of the cognitive assessments and the changes in scores from baseline to follow-up.
    Higher plasma insulin levels correlated with a lower score in delayed word recall and a 
more cognitive response conflict in the Stroop test. Higher HbA  1c  levels were also associated 
with a more cognitive response conflict in the Stroop performance (  table 3  ).
    Higher insulin levels at baseline were associated with decreased performance in the 
MMSE and DSS tests after 3 years. Higher HbA  1c   levels at baseline were significantly associ-
ated with declines in the DSS and Stroop tests at the 3-year follow-up compared to baseline 
( table 4 ).
    In the current study, we found no association between MRI-related factors (WMLs, 
PVLs, and number of SCIs) at baseline and follow-up ( tables 3 ,  4 ). At the baseline assessment, 
which was adjusted for age, sex, T2DM duration, body mass index, and education, the num-
ber of SCIs was significantly associated with Stroop (     = 0.284, p = 0.036) and DSS (     = 
0.248, p = 0.048), and the degree of PVHs was associated with DSS (     = –0.298, p = 0.037). 
Further adjustments with mean blood pressure and depressive mood assessed by GDS-15 
diminished the statistical significance of the association (  table 3  ).
  Discussion 
  In the current study, cross-sectional analyses indicated that higher plasma insulin levels 
correlated with a poorer Stroop test performance and poorer delayed word recall at baseline. 
Higher HbA  1c   levels were also associated with a poorer Stroop test performance at baseline. 
Longitudinal analyses showed that higher insulin levels at baseline were associated with a de-
crease in MMSE and DSS scores after 3 years. Higher HbA  1c   levels at baseline correlated with 
a greater decrease in DSS and Stroop scores after 3 years. The results of brain MRI assessments 
were not related to cognitive performance in the current study. To our knowledge, no prospec-
tive studies have investigated the association between clinical factors (including imaging data) 
and cognitive decline in elderly diabetics with relatively preserved cognitive function.
  Several cross-sectional studies have found that executive function/information process-
ing speed, which was measured by the DSS and Stroop tests in the current study, is impaired 5
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Table 1. P  atient characteristics
Patients, n 55
Gender, males/females 23/32
Age, years 74.485.7
Body mass index 22.483.3
Duration of T2DM, years 17.289.3
Education, years 9.782.2
HbA1c, % 7.180.8
Total cholesterol, mg/dl 203.2828.2
HDL cholesterol, mg/dl 53.7815.1
Triglycerides, mg/dl 114.1858.4
Immunoreactive insulin, U/ml 7.687.3
Systolic BP, mm Hg 138.0818.4
Diastolic BP, mm Hg 76.888.0
Presence of nephropathy, % 25.4
Presence of retinopathy, % 29.1
Presence of neuropathy, % 14.5
Diabetic therapy (diet/OHA/insulin), n 16/29/10
Antihypertensive treatment, % 61.8
PVH (0–3) 0.980.9
WML (0–3) 0.980.8
SCIs, n 1.881.8
M eans 8 SD. HDL = High-density lipoprotein; BP = blood pressure; OHA = oral hypoglycemic agent.
Table 2.   The scores of the cognitive assessment tests
Tests Baseline assessment Change in score
MMSE 26.782.2 –2.683.5
DSS 35.1810.6 –1.588.4
Stroop 18.9811.4 3.088.4
Word recall (delayed) 7.082.4 –0.881.6
M eans  8 SD. Range of scores: MMSE from 0 to 30, and word recall (delayed) from 0 to 10.
Table 3.   Linear regression analysis for baseline cognitive test scores with clinical variables
MMSE DSS Word recall
(delayed)
Stroop 
Insulin (log) 0.430 (0.352) –3.197 (0.139) –1.025 (0.022) 3.451 (0.005)
HbA1c 0.226 (0.593) –3.124 (0.112) –0.492 (0.239) 3.209 (0.004)
PVH 0.138 (0.640) –3.310 (0.066) –0.006 (0.988) 0.789 (0.471)
WML 0.248 (0.529) –1.022 (0.590) –0.174 (0.657)  –0.975 (0.388)
SCIs (n) –0.041 (0.833) –1.261 (0.163) –0.159 (0.406) 0.498 (0.359)
B   (p value) for each cognitive assessment is shown. Adjusted for age, gender, education, body mass in-
dex, GDS-15, mean blood pressure, and T2DM duration. Statistically significant differences are italicized.6
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in older diabetics   [23–25]  . A report on the inCHIANTI study has also demonstrated that in-
sulin resistance is associated with impaired executive function in non-diabetic elderly   [26]  . 
In the current study, we found that higher insulin levels are associated with poorer Stroop 
test performance at baseline and a more significant decline in DSS scores at the 3-year follow-
up. Higher HbA  1c   levels were also associated with a poorer Stroop test performance at base-
line and a more significant decline in DSS and Stroop test performance at the follow-up. In 
a recent systematic review   [12]  , the reported processing speed was found to be significantly 
affected in 63% of published studies and attention was affected in 50%. These observations 
suggest that executive function/information processing speed may be one of the cognitive 
domains responding to higher glucose and insulin levels. A recent follow-up study has dem-
onstrated that patients with T2DM exhibited moderate decrements in information process-
ing speed, attention, and executive functions in comparison to controls both at baseline and 
a 4-year follow-up examination   [14]  .
  A large cohort study, the ACCORD-MIND trial, has found that HbA  1c  levels were cross-
sectionally associated with poorer performance in several cognitive function tests similar to 
those utilized in the current study   [27]  . Maggi et al.   [13]   have reported, based on a prospec-
tive study, that higher HbA  1c   levels at baseline are associated with delayed verbal memory 
decline. Although the current results did not perfectly agree with the results of this study, 
the relevance of glycemic control in preserving cognitive function in elderly diabetics is 
strongly suggested. A recent prospective study by van den Berg et al.  [14] , however, has found 
that baseline HbA  1c   levels have no effects on 5 cognitive domains. The reason for this dis-
crepancy remains unclear at this point and should be further investigated. Their study in-
cluded relatively younger subjects (65 years old at baseline) than ours (74 years old at base-
line). It may be that older subjects are more vulnerable to diabetic metabolic abnormalities.
    Many studies have shown that higher plasma insulin levels or insulin resistance are as-
sociated with cognitive dysfunction. Several studies have also reported the association be-
tween MMSE scores and insulin levels   [28, 29]  . In the current study, we also noted an asso-
ciation between higher insulin levels and lower delayed word recall scores and poorer Stroop 
test performance at baseline. Higher insulin levels were also associated with declines in 
MMSE and DSS scores after 3 years. The mechanism by which insulin may impair cognition 
remains unclear; however, several hypotheses have been proposed to explain this phenom-
enon. Higher plasma insulin levels induce decreased insulin transport to the CNS, probably 
due to altered insulin transport mechanisms in the endothelial cells. The relative decrease in 
insulin levels within the brain may cause dysfunction of the central nervous system   [30]  . 
Table 4.   Linear regression analysis for changes in cognitive test scores with clinical variables
MMSE DSS Word recall
(delayed)
Stroop 
Insulin (log) –1.839 (0.012) –2.892 (0.047) 0.251 (0.433) –0.797 (0.724)
HbA1c –0.464 (0.503) –2.734 (0.040) –0.124 (0.655) 4.412 (0.028)
PVH 0.078 (0.902) –0.516 (0.686) –0.119 (0.630) –0.731 (0.670)
WML 0.770 (0.230) –0.029 (0.982) 0.206 (0.417)  0.541 (0.761)
SCIs (n) –0.247 (0.434) 0.177 (0.776) 0.094 (0.454) 0.600 (0.483)
B   (p value) for each cognitive assessment is shown. Adjusted for age, gender, education, body mass in-
dex, GDS-15, mean blood pressure, T2DM duration, and baseline test score. Statistically significant dif-
ferences are italicized.7
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Fewer insulin signals are possibly associated with decreased cholinergic activity   [31]   and 
long-term potentiation in the hippocampus, which is critical to memory formation   [32]  .
    Several studies have demonstrated that white matter lesions are associated with cogni-
tive processing speed assessed by DSS or similar tests  [11, 33, 34] , but in the current study, no 
MRI-derived indices were associated with any cognitive scores or declines in scores. Our 
previous study showed that WMLs and SCIs are factors contributing to cognitive impair-
ment in diabetics   [35]  , but in the current study, further adjustments with regard to blood 
pressure and depressive mood assessed by GDS-15 diminished the statistical significance of 
the association of ischemic lesions detected by MRI with cognitive test scores. The effects of 
ischemic small vessel lesions on cognition may occur, at least in part, via hypertension and 
depressive mood. Hypertension reportedly has a negative impact on cognition   [12]  . Depres-
sive mood is also a factor that affects cognition, including processing speed   [36]  . The contri-
bution of small vessel disease to depression has been scrutinized recently   [37]  .
    In the current study, higher HbA  1c   and insulin levels were found to be associated with 
declines in select domains of neurocognitive assessments both at baseline and during the 
3-year follow-up. These results suggest that diabetic disease control is important for the pres-
ervation of cognitive function in elderly diabetic patients. Cognitive impairment may affect 
the self-care ability in these patients   [38]   and lead to a deterioration in metabolic control.
  For further clarification of the effects of diabetic control on cognitive function, an inter-
ventional study is warranted.
    A limitation of the current study was that MRI and clinical indices were only assessed 
at baseline. Therefore, effects of changes in glycemic control or insulin resistance and the 
progression of small vessel disease in the brain were not evaluated. Although no association 
between MRI findings at baseline and cognitive decline was observed, the present results do 
not indicate that progression of small vessel disease has no impact on declines in cognitive 
function.
    Another potential limitation of the current study is that the participants were treated in 
a specialty clinic and their glycemic levels as well as other metabolic abnormalities were 
tightly controlled (7.1   8   0.8%). Therefore this group may not be representative of the gen-
eral diabetic population, which may bias the results.
    Since the current study involved a relatively small number of patients and control sub-
jects without diabetes were not included, our results should be confirmed by a prospective 
study including a larger patient cohort and non-diabetic controls.
  Conclusion 
  In our cross-sectional analysis, higher plasma insulin levels at baseline were negatively 
correlated with performance in Stroop and delayed word recall tests. Higher HbA  1c   levels 
were also negatively associated with performance in the Stroop test. Via longitudinal analy-
sis of elderly T2DM patients, worse glycemic control, i.e. higher HbA  1c  levels at baseline, was 
associated with a rapid decline in perceptual speed according to the DSS test and attention/
executive function according to the Stroop test. Higher insulin levels were associated with 
declines in MMSE and DSS performance. Diabetic disease control may be important for the 
preservation of cognitive function in elderly diabetics.
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